<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3404">
  <stage>Registered</stage>
  <submitdate>14/12/2011</submitdate>
  <approvaldate>14/12/2011</approvaldate>
  <nctid>NCT01494805</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration</studytitle>
    <scientifictitle>A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)</scientifictitle>
    <utrn />
    <trialacronym>AMD</trialacronym>
    <secondaryid>2008-135</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Macular Degeneration</healthcondition>
    <healthcondition>Age-related Maculopathies</healthcondition>
    <healthcondition>Age-related Maculopathy</healthcondition>
    <healthcondition>Maculopathies,Age-related</healthcondition>
    <healthcondition>Maculopathy,Age-related</healthcondition>
    <healthcondition>Retinal Degeneration</healthcondition>
    <healthcondition>Retinal Neovascularization</healthcondition>
    <healthcondition>Eye Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - rAAV.sFlt-1
Other interventions - rAAV.sFlt-1
Other interventions - Control (ranibizumab alone)

Experimental: Low Dose rAAV.sFlt-1 - 

Experimental: High Dose rAAV.sFlt-1 - 

Active Comparator: Control - ranibizumab only - 


Other interventions: rAAV.sFlt-1
1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Other interventions: rAAV.sFlt-1
1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Other interventions: Control (ranibizumab alone)
Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>No sign of unresolved ophthalmic complications, toxicity or systemic complications as measured by laboratory tests from 1 month post injection - Ocular examination:
Ocular inflammation
Intraocular pressure
Visual acuity
Retinal bleeding
Abnormal laboratory data</outcome>
      <timepoint>Primary endpoint at 1 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maintenance or improvement of vision without the necessity of ranibizumab re-injections - Best-corrected visual acuity
CNV lesion
Foveal thickness</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age greater than or equal to 55 years;

          -  Subfoveal CNV secondary to AMD and with best corrected visual acuity of 3/60 - 6/9
             with 6/60 or better in the other eye;

          -  Fluorescein angiogram of the study eye must show evidence of a leaking subfoveal
             choroidal neovascular lesion, or CNV currently under active management with anti-VEGF
             therapy;

          -  Must be a candidate for anti-VEGF intravitreal injections;

          -  No previous retinal treatment of photodynamic therapy or laser;

          -  Able to provide informed consent;

          -  Able to comply with protocol requirements, including follow-up visits.</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Liver enzymes &gt; 2 X upper limit of normal;

          -  Any prior treatment for AMD in the study / control eye, excluding anti-VEGF
             injections;

          -  Extensive sub-foveal scarring, extensive geographic atrophy, or thick subretinal blood
             in the study eye as determined by the investigator;

          -  Significant retinal disease other than sub-foveal CNV AMD;</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Lions Eye Institute - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Lions Eye Institute, Perth, Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Adverum Biotechnologies, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will involve approximately 40 subjects aged 55 or above who have exudative
      age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two
      doses of rAAV.sFlt-1 or assigned to the control group.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01494805</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ian Constable, Professor</name>
      <address>Lions Eye Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>